Catechol

Catechol

SCHEMBL665292

CCCC.Oc1ccccc1O

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.67
CA2 P00918 4/20 0.67
TDP1 Q9NUW8 3/20 0.67
ALOX15 P16050 3/20 0.67
LMNA P02545 3/20 0.67
EGFR P00533 2/20 0.67
FYN P06241 2/20 0.67
MMP9 P14780 2/20 0.67
HPGD P15428 2/20 0.67
RECQL P46063 2/20 0.67
HSD17B10 Q99714 2/20 0.67
HIF1A Q16665 2/20 0.67
KDM4E B2RXH2 2/20 0.67
NPC1 O15118 2/20 0.67
MAPT P10636 2/20 0.67
CA4 P22748 2/20 0.67
SMN1; SMN2 Q16637 2/20 0.67
CA12 O43570 1/20 0.67
GMNN O75496 1/20 0.67
POLB P06746 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Catechol SCHEMBL7569845 0.90 CA2 (0.71) ALDH1A1CA2TDP1ALOX15LMNA
Catechol SCHEMBL11566875 0.90 CA2 (0.71) ALDH1A1CA2TDP1ALOX15LMNA
Catechol SCHEMBL27754508 0.88 ALDH1A1 (0.59) ALDH1A1CA2TDP1ALOX15LMNA
Catechol SCHEMBL2581350 0.87 ALDH1A1 (0.67) ALDH1A1CA2TDP1ALOX15LMNA
Pentadecane SCHEMBL27500799 0.85 ALDH1A1 (0.56) ALDH1A1CA2TDP1ALOX15LMNA
Catechol SCHEMBL27792619 0.85 TDP1 (0.56) ALDH1A1CA2TDP1ALOX15LMNA
Catechol SCHEMBL27517238 0.85 ALDH1A1 (0.56) ALDH1A1CA2TDP1ALOX15LMNA
Octane SCHEMBL27871796 0.85 ALDH1A1 (0.56) ALDH1A1CA2TDP1ALOX15LMNA
Catechol SCHEMBL23241892 0.84 ALDH1A1 (0.62) ALDH1A1CA2TDP1ALOX15LMNA
Catechol SCHEMBL6658686 0.84 CA2 (0.62) ALDH1A1CA2TDP1ALOX15LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 297 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102186503-A Stable aqueous formulations of water insoluble or poorly soluble drugs ERIMOS PHARMACEUTICALS LLC 2011-09-14 CN claimed
CN-101389319-A Methods of treating influenza viral infections ERIMOS PHARMACEUTICALS LLC (US) 2009-03-18 CN claimed
CN-101150955-A Oral formulations for delivery of catecholic butanes including NDGA compounds ERIMOS PHARMACEUTICALS LLC (US) 2008-03-26 CN claimed
CN-101150956-A Formulations for injection of catecholic butanes, including NDGA compounds, into animals ERIMOS PHARMACEUTICALS LLC (US) 2008-03-26 CN claimed
CN-1852705-A Methods and compositions for delivery of catecholic butanes for treatment of obesity ERIMOS PHARMACEUTICAL LLP (US) 2006-10-25 CN claimed
CN-1849115-A Methods and compositions for delivery of catecholic butanes for treatment of tumors UNIV JOHNS HOPKINS (US) 2006-10-18 CN claimed
CN-1838948-A Methods and compositions for delivery of catecholic butanes for treatment of diseases ERIMOS PHARMACEUTICAL LLP (US) 2006-09-27 CN claimed
US-5928654-A Modulating body/cranial hair growth with lipoxygenase/cyclooxygenase inhibitors SOCIETE L'OREAL S.A. (FR) 1999-07-27 US claimed
US-4880637-A ALCOHOLS, ETHERS OR ESTERS, AS ANTITUMOR AGENTS, SKIN DISORDERS CHEMEX PHARMACEUTICALS, INC. (US) 1989-11-14 US claimed
EP-0288534-A4 COMPOSITIONS OF CATECHOLIC BUTANES WITH ZINC. CHEMEX PHARMACEUTICALS INC (US) 1989-02-23 EP claimed
EP-0288534-A1 COMPOSITIONS OF CATECHOLIC BUTANES WITH ZINC. CHEMEX PHARMACEUTICALS INC (US) 1988-11-02 EP claimed
WO-1988003026-A1 COMPOSITIONS OF CATECHOLIC BUTANES WITH ZINC CHEMEX PHARMACEUTICALS, INC. (US) 1988-05-05 WO claimed
US-12037405-B2 Anti-CD70 antibody drug conjugates AMBRX, INC. 2024-07-16 US disclosed
US-20240190981-A1 Humanized Anti-CD70 Binding Agents and Uses Thereof SEAGEN INC (US) 2024-06-13 US disclosed
US-20240182580-A1 ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES SUTRO BIOPHARMA INC (US) 2024-06-06 US disclosed
WO-2024091979-A1 CD276 (B7-H3) ANTIBODY-DRUG CONJUGATES BRICKBIO, INC. (US) 2024-05-02 WO disclosed
US-5928654-A Modulating body/cranial hair growth with lipoxygenase/cyclooxygenase inhibitors SOCIETE L'OREAL S.A. (FR) 1999-07-27 US disclosed
EP-0288534-B1 COMPOSITIONS OF CATECHOLIC BUTANES WITH ZINC CHEMEX PHARMACEUTICALS, INC. (US) 1991-12-18 EP disclosed
JP-S6479112-A TREATMENT OF TUMOR BY CATECHOL BUTANE COMPOSITION KEMETSUKUSU PHARMACEUT INC 1989-03-24 JP disclosed
US-3970640-A Process for the production of polyphenylene ethers having a desired polymerization degree MITSUBISHI GAS CHEMICAL COMPANY, INC. (JA) 1976-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12037405-B2 Anti-CD70 antibody drug conjugates CD74, CD63, CD47 ALDH1A1 868/4885CA2 3077/4885TDP1 3783/4885
US-20240182580-A1 ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES CD74, CD63, CD99 ALDH1A1 1241/4885CA2 2152/4885TDP1 3110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.